DengueRACSMEINCT07358910
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
An observational study of Dengue and Chikungunya, run by Institut Pasteur du Cambodge at 1 site in Cambodia.
Trial summary
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies. Read more about this study
- Who is it for?
- Ages 2 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Dengue, Chikungunya, Zika Virus Infection
- How many people
- 10,000 participants
- Where
- 1 siteCambodia
- Study dates
- 18 Dec 2025to 30 Sep 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 75 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: The study population comprises approximately 10,000 participants aged 2 to 75 years, drawn from 4,160 households across Cambodia's 25 provinces. Households will be randomly selected from 104 villages to ensure a nationally representative sample that reflects the country's diverse geographic and demographic characteristics. Participants will provide detailed socio-demographic information, enabling post-stratification weighted analysis of the sample's structure by sex, age, and geographic area to facilitate the extrapolation of findings to the entire population, ensuring that the study's conclusions are broadly applicable.
Who may be able to join
- Residency in the village for more than 6 months;
- Age between 2 and 75 years old at the time of inclusion;
- For adults: provision of written consent;
- For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;
Who cannot join
- Unable to understand or consent;
- Under guardianship or deprived of liberty;
- Medical conditions that impede survey participation;
- Refusal to participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Cambodia1 site, 1 recruiting
- Recruiting
Institut Pasteur du Cambodge
Phnom Penh, Phnom Penh, 12201
Sowath LY, MD, Ph.D, +855 69 322 031, lsowath@pasteur-kh.org
Sopheak SORN, MSc., +855 12 268 660, ssopheak@pasteur-kh.org
About this study
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.
RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.
Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.
Read the detailed description
RACSMEI is a nationwide, One Health, multi-pathogen initiative designed to generate integrated evidence for public-health decision-making in Cambodia. Beyond producing epidemiological findings, the project will establish a structured biobank and curated datasets intended to support long-term collaborative research, knowledge sharing, and evidence-informed policy. The program includes capacity building and technology transfer to strengthen national institutions and foster regional scientific leadership and international collaboration. Engagement with communities and national stakeholders is planned to facilitate future studies and promote the uptake of results in practice. Overall, RACSMEI aims to provide a scalable model for integrated infectious-disease assessment in low- and middle-income settings, creating durable infrastructure, partnerships, and decision-support resources that can be used beyond the project period.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis, West Nile Virus, Tick-borne Encephalitis (TBE)
- Keywords
- Infectious disease, One Health, Population-based survey, Nationally representative survey, Seroepidemiology, Multiplex serology, Seroprevalence, Vector-borne diseases, Zoonoses, Vaccine-preventable diseases, Neglected tropical diseases, Transmission dynamics, Force of infection, Mathematical modelling, Spatial epidemiology, Precision public health, Cambodia
- Medical subject headings
- Dengue, Chikungunya Fever, Zika Virus Infection, Encephalitis, Japanese, Encephalitis, Tick-Borne, Severe Fever with Thrombocytopenia Syndrome, Henipavirus Infections, Hantavirus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Human Community Cohort (National Population Sample) | Probability-based, multi-stage population sample of ~10,000 participants (2-75 years old) recruited across urban and rural communities nationwide. Data include standardized questionnaires (demography, health conditions, mobility, animal contact, healthcare access) and serum biospecimens for multiplex serology; |
What is being measured
The primary outcome is the main question the study is designed to answer.
Seroprevalence of antibodies against an established panel of priority pathogens in the surveyed human populations:
The proportion of sampled individuals with detectable antibodies against this priority panel of pathogens, measured using multiplex serological assays.
Measured: At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start18 Dec 2025
- Primary completion16 Apr 2026 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DengueStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Family based
- Time perspective
- Cross-sectional
- Enrolment
- 10,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Pasteur du Cambodge
- Sponsor type
- University, hospital or other
- Collaborators
- Institut Pasteur, CDC - Ministry of Health of Cambodia, UMR ASTRE (CIRAD), Malaria Consortium, Ministry of Agriculture, Forestry and Fisheries Cambodia
- Responsible party
- Sponsor
- Investigators
- Claude Flamand, Ph.D., Principal investigator, Institut Pasteur du Cambodge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07358910
- Sponsor's protocol ID
- IPasteurCambodge
- Other IDs
- 312353/Z/24/Z
- Acronym
- RACSMEI
- Status last verified
- Jan 2025
- First submitted
- 14 Jan 2026
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No